View Older Stories

Aug 14, 2026 05:17PM Form SCHEDULE 13D/A Septerna, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:50PM Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:50PM Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:50PM Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:49PM Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:49PM Form SCHEDULE 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:49PM Form SCHEDULE 13G/A Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:49PM Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:48PM Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:48PM Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:48PM Form SCHEDULE 13G/A BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:48PM Form SCHEDULE 13G/A Atrium Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:48PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:45PM Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:44PM Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 14, 2026 04:37PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30

Aug 13, 2026 04:16PM Form SCHEDULE 13G TCGX Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 11, 2026 04:40PM Form SCHEDULE 13D/A Wave Life Sciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 10, 2026 04:27PM Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 10, 2026 04:24PM Form SCHEDULE 13G Obsidian Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 7, 2026 04:14PM Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 6, 2026 05:50PM Form SCHEDULE 13G DBV Technologies S.A. Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 3, 2026 04:38PM Form SCHEDULE 13G Scribe Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 3, 2026 04:36PM Form SCHEDULE 13G CAPRICOR THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Aug 3, 2026 09:00AM Obsidian Therapeutics completes Galera merger, raises $350M

Jul 31, 2026 04:34PM Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 29, 2026 07:30AM Processa acquires Vidya Therapeutics in $200M private placement deal

Jul 27, 2026 08:30AM Entera Bio prices $275M private placement led by BVF Partners

Jul 27, 2026 08:30AM Entera Bio prices $275 million private placement led by BVF Partners

Jul 27, 2026 07:01AM Jury awards Biohaven and Yale $4M in trade secret case

Jul 23, 2026 09:23PM Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 22, 2026 05:34PM Form SCHEDULE 13D/A Freenome, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 21, 2026 04:56PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 20, 2026 04:17PM Form SCHEDULE 13G AGENUS INC Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 20, 2026 04:01PM Freenome begins trading on Nasdaq after $310M SPAC merger

Jul 17, 2026 05:53PM Form SCHEDULE 13G Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 14, 2026 08:00AM Inhibikase sells $50M in shares to RA Capital via ATM facility

Jul 13, 2026 09:05AM Research Alliance Corporation IV prices $75M IPO on Nasdaq

Jul 13, 2026 06:00AM Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial

Jul 7, 2026 04:42PM Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jul 7, 2026 04:01PM Vor Bio names David Zaccardelli to its board of directors

Jul 2, 2026 08:27PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Jun 29, 2026 07:02AM Talawar Therapeutics to go public via SPAC deal with $225M PIPE

Jun 26, 2026 05:39PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Jun 24, 2026 08:00PM Ollin Biosciences raises $330M Series B to fund eye disease trials

Jun 24, 2026 06:49PM Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Jun 24, 2026 07:01AM Ollin Biosciences raises $330M Series B for eye disease drug trials

Jun 23, 2026 07:30AM Boundless Bio agrees to merge with Serapha Bio in all-stock deal

Jun 22, 2026 07:02PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Jun 18, 2026 04:10PM Form SCHEDULE 13D Parabilis Medicines, Filed by: RA CAPITAL MANAGEMENT, L.P.

View Older Stories